Navigation Links
Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA

OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS) presented an update of data from its ongoing clinical Phase I/II study with ELACYT in hematologic cancers during a poster session at the Annual Meeting of the European Hematology Association (EHA) in Vienna. ELACYT is a novel cytotoxic agent in development for the treatment of hematologic cancers as well as for solid tumours. In this ongoing Phase I/II study Clavis Pharma reports that patients with hematologic malignancies have tolerated ELACYT well at doses up to 1150 mg/m²/day (2 hour infusion) and 675 mg/m²/day (continuous infusion). Initial results from this study were presented at AACR in April this year.

The phase I/II study is currently in its dose escalating phase with the aim to define the maximum tolerated dose, the optimal regimen and to characterize the safety profile of ELACYT given as a single agent in patients with hematologic malignancies. The second part of the study will evaluate the effect of ELACYT.

"The updated clinical results confirm the good safety profile seen with ELACYT so far" says Tom Pike, CEO of Clavis Pharma. "The progress of the study shows excellent recruitment in both continents high and we hope to be able to open the phase II part shortly."

The centres involved in this multicentre Phase I/II study are MD Anderson Cancer Centre, Houston, Texas, USA, Institute Paoli Calmettes, Marseille, France and Duke University Hospital, USA. A number of new sites have been recruited for the Phase II - efficacy part of the study. The Co-ordinating Investigator of the study is Professor Frank Giles, Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio

Contact: Tom Pike Chief Executive Officer Tel: + 47 915 19 652 / + 47 24 11 09 50 tom.pike@clavispharma.com www.clavispharma.com


'"/>




Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are ... BCC Research reveals in its new report that markets in ... see strong growth due to rising government healthcare spending, increased levels of ... Continue Reading ... ...
(Date:1/23/2017)... Spain , January 23, 2017 /PRNewswire/ ... biopharmaceutical company focused on treatments for calcification disorders, ... enrolled in the Phase IIb "CaLIPSO Study" clinical ... of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients ... in the last stage of chronic kidney disease, ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and ... big data and powered by artificial intelligence and this trend is going to ... ,Hospital of the Future, at the concluding day of the 47 th ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the Journal ... on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – helped ... experiencing an increased sense of purpose both during and after treatment. , The ...
(Date:1/24/2017)... Ariz. (PRWEB) , ... January 23, 2017 , ... ... recently analyzed statistics from 140 Buzzies users who entered metrics into the product’s ... earlier clinical data. The new data showed that within just 30 seconds of ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania addiction ... address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found at ... with its redesigned and retooled website. The treatment center has also revamped its ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... for life science companies, has achieved ISO 17100:2015 certification following a comprehensive ... 17100 is the globally recognized standard that establishes guidance for critical processes ...
Breaking Medicine News(10 mins):